<DOC>
	<DOCNO>NCT02677181</DOCNO>
	<brief_summary>The purpose study determine efficacy safety combine ATG （antithymocyte globulin ） regimen aGVHD ( acute graft-versus-host disease ) prophylaxis match sibling donor peripheral blood stem cell transplantation ( MSD-PBSCT ) .</brief_summary>
	<brief_title>Efficacy Safety Study ATG Prophylaxis aGVHD Matched Sibling Donor PBSCT</brief_title>
	<detailed_description>Transplantation G-CSF （Granulocyte colony stimulate factor ）mobilized peripheral blood stem cell ( PBSCT ) stable transplant set match sibling donor transplantation . Unmanipulated haploidentical donor PBSCT ( haplo-PBSCT ) apply patient hematologic malignancy . In previous cohort study , haplo-PBSCT associate low incidence severe acute GVHD extensive chronic GVHD compare match sibling donor PBSCT ( MSD-PBSCT ) . Haplo-PBSCT GVHD prophylaxis regimen MSD-PBSCT , except ATG . It suggest potential advantage ATG prophylaxis GVHD improvement long-term quality life transplant recipient , motivate u observe efficacy combine ATG regimen GVHD prophylaxis MSD-PBSCT .</detailed_description>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1. acute myeloid leukemia ( AML ) CR1 ( complete remission 1 ) CR2 ( complete remission 2 ) phase regardless cytogenetics ; 2 . CML CP ( chronic myelogenous leukemia , chronic phase ) ; 3 . MDSRAEB ( myelodysplastic syndrome refractory anemia excess blast ) . 4 . All patient age 40 70 year 5 . Have match sibling donor . 6 . Patients without uncontrolled infection without severe pulmonary , renal , hepatic cardiac disease . 1 . Patients age less 40 year old ; 2 . Patients uncontrolled infection severe pulmonary , renal , hepatic cardiac disease ; 3 . AML patient ( 15 ; 17 ) ;</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>ATG</keyword>
	<keyword>Matched sibling donor</keyword>
	<keyword>peripheral blood stem cell transplantation</keyword>
</DOC>